You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases
SBC: BIOSTRATAGIES LC Topic: NICHDMucopolysaccharidosis Type IVA (MPS-IVA; also called Morquio A Syndrome) is a rare genetic childhood disorder characterized by multi-systemic pathologies affecting the respiratory, cardiovascular, musculoskeletal, and central nervous systems leading to devastating quality-of-life and early death. The disease is due to deficiencies in N-acetylgalactosamine-6-sulfate sulfatase (GALNS) causing progre ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A proprietary digital platform for precision patient identification and enrollment of clinical trials for rare kidney diseases
SBC: Nephropathology Associates, PLC Topic: 400Project Summary The goal of this Direct to Phase II program is to develop and test the efficacy of a Precision Medicine Clinical Trials Enrollment Platform for kidney diseases. Approximately half of randomized controlled trials do not meet their recruiting target. Enrolling trials targeting rare kidney diseases is particularly challenging with many conditions subject to stratification and sub-typi ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)
SBC: BIOSTRATAGIES LC Topic: 105PROJECT SUMMARY In this Direct-to-Phase II SBIR, BioStrategies LC proposes to advance the development of a novel AAV- based gene therapy for mucopolysaccharidosis type IIIA (MPS IIIA, also known as Sanfilippo A syndrome). In contrast to other gene therapies in development for MPS IIIA, BioStrategies’ approach is designed to achieve a systemic therapeutic effect, including delivery of a functiona ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies
SBC: EXAVIR THERAPEUTICS INC. Topic: NIAIDPROJECT SUMMARY While there are now successful treatment regimens and prevention strategies for people living with HIV/AIDS, the HIV pandemic remains a public health crisis in the United States and worldwide, with nearly 40,000 new infections each year in the US alone. To prevent the spread of HIV in vulnerable populations, the US Preventive Services Task Force has recommended HIV pre-exposure pro ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
RAE cHealth:A digital community support tool to promote recovery from substance use disorder
SBC: CONTINUEYOU, LLC Topic: NIDAPROJECT SUMMARY The research project outlined in this Fast track SBIR submission will develop the RAE cHealth platform into a tool to address digital inequities and support peer-based collaborative recovery for individuals with substance use disorder. In this proposal, the investigators intend to develop and deploy the RAE cHealth system- consisting of a wearable sensor and a smartphone app. RAE c ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Advanced Development of Gemini-DHAP
SBC: SFC FLUIDICS, INC. Topic: 200Advanced Development of GeminiTM-DHAP Project Summary:The Specific Aim of this Direct to Phase II project is to develop a discrete, low-profile, dual hormone artificial pancreas device, the GeminiTM-DHAP, using SFC Fluidics' enabling microfluidic technologies to deliver both insulin and glucagon as recommended by a dual-hormone algorithm in response to continuous glucose monitor readings. The Gemi ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Deep-UV Microscopy for Real-Time Adequacy Analysis of Bone Marrow Aspirates
SBC: Cellia Science, Inc. Topic: NIBIBProject Summary/Abstract Bone marrow aspirates are critical to the diagnosis, staging, and monitoring of hematologic conditions and cancers (e.g., leukemia, aplastic anemia, sickle cell disease, and metastasis of solid tumors), but 8-50% of aspirations are unsuccessful due to operator technique, hemodilution, or underlying pathology. Because this process is manual and error-prone, there is an oppo ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Formable Preform for Advanced Ceramic Matrix Composite Structures
SBC: PEPIN ASSOCIATES INC Topic: DLA23A003Pepin Associates, Inc. has developed a unique, aligned discontinuous textile reinforcement for composite structures. This reinforcement architecture is composed of short, overlapped tow segments. The architecture allows the textile to stretch in its reinforcement direction. This ability permits rapid fabrication of complex shaped thermal protection system structures from simple low cost sh ...
STTR Phase I 2023 Department of DefenseDefense Logistics Agency -
Image-based risk assessment to identify women at high-risk for breast cancer
SBC: WAVED MEDICAL LLC Topic: NCI7. PROJECT SUMMARY Breast cancer is the most common cancer worldwide and the most common cancer diagnosed in American women. While there has been good progress regarding detection and treatment methods, breast cancer remains the primary cause of death from malignant tumors. Hence, there is a critical need for the development of novel predictive and prognostic factors. Risk assessments are currentl ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Tungsten 3% Rhenium Wire Manufacturing
SBC: Elmet Technologies LLC Topic: DLA231D08When GTP discontinued the manufacture of WRe wire, it ended US-based production of a material critical in the operations of MWT/TWT equipment for defense applications. The objective of this project is to produce a WRe wire that matches as closely as possible the wire produced by GTP while also potentially developing a process that meets or exceeds the yields achieved by GTP. The wire produced ...
SBIR Phase II 2023 Department of DefenseDefense Logistics Agency